1370 - Ocriplasmin for symptomatic vitreomacular adhesion (sVMA) including macular hole

Page last updated: 29 May 2018

Application Detail



Description of Medical Service

Optical coherence tomography (OCT) is part of standard clinical practice for diagnosing a wide range of macular and retinal diseases. It is proposed that OCT be used as a procedure in patients with sVMA including those associated with full thickness macular hole (FTMH) for the purpose of identifying eligibility for treatment with ocriplasmin (on the Pharmaceutical Benefits Scheme); and for assessment of treatment outcome.

Description of Medical Condition

Vitreomacular interface disorders describe a group of pathologies each with their own distinctive features that distort or blur vision and potentially impair central visual acuity, including vitreomacular adhesion/traction and macular holes.

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

Final Protocol (PDF 939 KB)
Final Protocol (Word 1986 KB)

Assessment Report


Public Summary Document

November 2014:
Public Summary Document (PDF 134 KB)
Public Summary Document (Word 111 KB)

March 2016:
Public Summary Document (PDF 63 KB)
Public Summary Document (Word 68 KB)

OCT broader implementation issues - MSAC's advice to the Minister:
OCT broader implementation issues (PDF 66 KB)
OCT broader implementation issues (Word 66 KB)

Consumer Friendly Public Summary Document (PSD)

Consumer Friendly PSD (PDF 409 KB)
Consumer Friendly PSD (Word 18 KB)

Consumer Friendly PSDs - The Basics

The Basics (PDF 190 KB)
The Basics (Word 29 KB)

Meetings for this Application


12 December 2013


8 October 2014


26 November 2014
30 March 2016